<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066274</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000315384</org_study_id>
    <secondary_id>FRE-FNCLCC-ACCORD-08/0103</secondary_id>
    <secondary_id>EU-20233</secondary_id>
    <nct_id>NCT00066274</nct_id>
  </id_info>
  <brief_title>Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Giving the drugs in different combinations may kill more tumor
      cells.

      PURPOSE: This randomized phase II trial is studying combination chemotherapy containing
      irinotecan and oxaliplatin to see how well it works compared to two standard combination
      chemotherapy regimens in treating patients with unresectable metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy, in terms of response rate (partial response and complete
           response), of irinotecan and oxaliplatin vs irinotecan, fluorouracil, and leucovorin
           calcium vs oxaliplatin, fluorouracil, and leucovorin calcium in patients with metastatic
           colorectal cancer.

        -  Compare the progression-free survival of patients treated with these regimens.

        -  Compare the tolerability of these regimens in these patients.

        -  Compare the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 3 treatment
      arms.

        -  Arm I: Patients receive irinotecan IV over 90 minutes and oxaliplatin IV over 2 hours on
           day 1.

        -  Arm II: Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2
           hours on day 1 and fluorouracil IV over 46 hours on days 1-2.

        -  Arm III: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2
           hours on day 1 and fluorouracil IV over 46 hours on days 1-2.

      In all arms, treatment repeats every 2 weeks for 26 courses in the absence of disease
      progression or unacceptable toxicity.

      Quality of life is assessed at baseline and then every 3 months for 1 year.

      Patients are followed at 2 months.

      PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study within 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed colorectal carcinoma

               -  Metastatic disease

          -  Not amenable to surgery

          -  Unidimensionally measurable disease

          -  No bone metastases

          -  No brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 75

        Performance status

          -  WHO 0-2

        Life expectancy

          -  At least 12 weeks

        Hematopoietic

          -  Neutrophil count at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 10 g/dL

        Hepatic

          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN) (1.5 times ULN if
             hepatic metastases are present)

          -  SGPT and SGOT no greater than 3 times ULN (5 times ULN if hepatic metastases are
             present)

        Renal

          -  Creatinine no greater than 1.25 times ULN

        Cardiac

          -  No concurrent cardiac abnormalities that would preclude study therapy

        Pulmonary

          -  No concurrent pulmonary abnormalities that would preclude study therapy

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No chronic enteropathy

          -  No other prior cancer within the past 5 years except carcinoma in situ of the cervix
             or curatively treated basal cell skin cancer

          -  No concurrent severe uncontrolled infection

          -  No obstruction or partial obstruction that would interfere with study therapy

          -  No psychological, social, familial, or geographical situation that would preclude
             study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent anticancer biological response modifiers

        Chemotherapy

          -  No prior chemotherapy (except adjuvant chemotherapy completed more than 6 months ago)

          -  No prior irinotecan

          -  No prior oxaliplatin

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  No concurrent anticancer hormonal therapy

        Radiotherapy

          -  At least 4 weeks since prior pelvic radiotherapy

          -  No prior abdominopelvic radiotherapy

        Surgery

          -  At least 4 weeks since prior surgery

          -  No prior extensive intestinal resection (i.e., more than 1 prior hemicolectomy or
             extensive resection of the small intestines)

        Other

          -  No other concurrent experimental medication

          -  No other concurrent anticancer therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Becouarn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergoni√©</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de L' Agglomeration Montargoise</name>
      <address>
        <city>Amilly</city>
        <zip>45207</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pole Sante Sarthe et Loir Hopital Pierre Daguet</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte-Marguerite</name>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>F-85025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR D'Orleans - Hopital de la Source</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <zip>24004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHG Roanne</name>
      <address>
        <city>Roanne</city>
        <zip>F-42300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Rodez</name>
      <address>
        <city>Rodez</city>
        <zip>12027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Metz Thionville</name>
      <address>
        <city>Thionville</city>
        <zip>57126</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General Lucien Hussel</name>
      <address>
        <city>Vienne</city>
        <zip>38200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>B√©couarn Y, Senesse P, Th√©zenas S, Boucher E, Adenis A, Cany L, Jacob JH, Cvitkovic F, Montoto-Grillot C, Ychou M; Digestive Group of the F√©d√©ration Nationale des Centres de Lutte Contre le Cancer. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the F√©d√©ration Nationale des Centres de Lutte Contre le Cancer. Ann Oncol. 2007 Dec;18(12):2000-5. Epub 2007 Sep 4.</citation>
    <PMID>17785765</PMID>
  </results_reference>
  <verification_date>May 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>January 10, 2009</last_update_submitted>
  <last_update_submitted_qc>January 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2009</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

